Cancer Genetics Announces Acquisition of NovellusDx to Expand its Oncology Platform
NovellusDx will provide its functional genomics assay FACT (Functional Annotation for Cancer Treatment) to Primetech, for pre-clinical market with sales, marketing and research/technical support in Japan exclusively
FACT has capability to determine trial outcomes in patients, now this system will help in developing anti-cancer drugs and mechanism of action
Japan is the first territory where NovellusDx will be marketing as agent agreement
Click here to read full press release/ article | Ref:Primetech| Image: Business wire
Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at email@example.com.